Fairmont The Queen Elizabeth Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2018



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Cancer Immunotherapy: Combinations (C5)


Organizer(s) Chris Boshoff, Lieping Chen and Lisa Coussens
March 23—27, 2018
Fairmont The Queen Elizabeth • Montreal, Québec Canada
Discounted Abstract Deadline: Nov 21, 2017
Abstract Deadline: Dec 19, 2017
Scholarship Deadline: Nov 21, 2017
Discounted Registration Deadline: Jan 16, 2018

Held in honor of cancer immunotherapy research pioneers Dr. Alan Korman and Dr. Nils Lonberg, thanks to generous support from an anonymous donor.

Sponsored by BioLegend, Inc., Bristol-Myers Squibb Company, Cancer Research UK, Cell Research, Genentech, Inc., Incyte Corporation, MedImmune, Merck & Co., Inc., OncoMed Pharmaceuticals, Inc., Pfizer Inc., Regeneron Pharmaceuticals, Inc., Surface Oncology,Takeda Pharmaceutical Company Limited, TESARO, Inc. and Thermo Fisher Scientific Inc.

Summary of Meeting:
By 2025, most patients with cancer will receive immunotherapy as part of their treatment regimen. This symposium will cover the most critical topics integral to this vision: How can we integrate, sequence or combine immunotherapy with standard-of-care cytotoxic therapy, radiotherapy and targeted therapies? Which preclinical models are best predictive of combination approaches? How do we combine immune agonists as well as molecules inhibiting immune-suppressive pathways with checkpoint inhibitors? What are the rational combinations for cancer vaccines and viro-therapy? Which combinatorial approaches could prevent or treat adaptive mechanisms of resistance? Most immunotherapies are being developed in isolation, or being tested as single agents in preclinical models or in clinical studies. This conference helps to address the gaps in knowledge of how and when to combine therapies, and how to integrate immunotherapy into current standard-of-care or novel targeted therapy approaches – both preclinical and clinical. Overall, the objectives of this meeting are to: 1) Elucidate rational combinations for immunotherapy; 2) Discuss preclinical and other models to inform combinatorial approaches; 3) Understand the relevance for biomarker approaches; and 4) Provide insights into the latest preclinical and clinical data for immunotherapy combinations.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


The meeting will begin on Friday, March 23 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Tuesday, March 27 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Wednesday, March 28 in order to fully experience the meeting.

FRIDAY, MARCH 23

16:00—20:00
Arrival and Registration

Agora
18:00—20:00
Welcome Mixer
No registration fees are used to fund alcohol served at this function.

Agora

SATURDAY, MARCH 24

07:30—08:30
Breakfast

Square Dorchester/Parc Mont Royal
08:30—10:00
Welcome and Keynote Session
Meeting has ended...abstracts no longer viewable online.

Place du Canada
* Chris H. Boshoff, Pfizer Inc., USA

* Lieping Chen, Yale University, USA

* Lisa M. Coussens, Oregon Health & Science University, USA

Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, USA
Immunologic Checkpoint Blockade: Exploring Combinations and Mechanisms

Elizabeth M. Jaffee, Johns Hopkins University, USA
Combinatorial Immunotherapy Converts Pancreatic Cancers into an Immunologic Disease

Coffee Break

10:20—12:00
Rational Immunotherapy Combinations: Preclinical Models as Predictive or Responses
Meeting has ended...abstracts no longer viewable online.

Place du Canada
* Judith A. Varner, University of California, San Diego, USA

Lieping Chen, Yale University, USA
Design of Combination Therapy-Based Adaptive Resistance Mechanisms in Tumor Microenvironment

Michele W. Teng, QIMR Berghofer Medical Research Institute, Australia
Dissecting the Immunological Mechanisms underlying the Efficacy of Neoadjuvant Immunotherapy

Simone A. Minnie, QIMR Berghofer Medical Research Institute, Australia
Short Talk: Stem Cell Transplantation Establishes T Cell-Dependent Myeloma Immune-Equilibrium that Can Be Enhanced with Immunotherapy

Hyejin Choi, Memorial Sloan Kettering Cancer Center, USA
Short Talk: Optimizing Targeted Therapy and Immune Checkpoint Blockade Therapy in Kras Mutant Lung Cancer

12:00—17:00
On Own for Lunch

12:00—13:00
Poster Setup

Square Dorchester/Parc Mont Royal
13:00—22:00
Poster Viewing

Square Dorchester/Parc Mont Royal
14:30—16:30
Workshop: Novel and Sequencing Approaches

Place du Canada
* Chris H. Boshoff, Pfizer Inc., USA

Bradley N. Mills, University of Rochester, USA
Development of a New Strategy to Treat Locally Advanced Pancreatic Cancer

Adrienne Rothschilds, Massachusetts Institute of Technology, USA
Order of Administration of Combination Cytokine Therapies Can Decouple Toxicity from Efficacy in Syngeneic Mouse Tumor Models

Alvaro de Mingo Pulido, Moffitt Cancer Center, USA
TIM-3 Regulates cDC1 Function and Response to Chemotherapy in Breast Cancer

Jiemiao Hu, University of Texas MD Anderson Cancer Center, USA
Combinational Therapy for Boosting T Cell Transfer to Overcome Heterogeneity and Immune Suppression of Solid Tumors

Christopher D. Zahm, University of Wisconsin-Madison, USA
TLR Stimulation of Antigen-Presenting Cells Leads to IL-12 Expression that Decreases PD-1 Mediated Regulation

Hayley S. Ma, Sidney Kimmel Comprehensive Cancer Center, USA
Combination CD40 Agonist and PD-1 Antagonist Antibody Therapy Enhances Vaccine-Induced T Cell Responses in Non-Immunogenic Cancers

16:30—17:00
Coffee Available

Square Dorchester/Parc Mont Royal
17:00—19:00
Incorporating Checkpoint Inhibitors into SOC Chemo- and Radiotherapy Regimens
Meeting has ended...abstracts no longer viewable online.

Place du Canada
* Jane L. Grogan, Genentech, Inc., USA

Ronald Herbst, MedImmune, USA
Combination Therapy for Cancer: Beyond Checkpoint Inhibition

Andy Minn, University of Pennsylvania, USA
Interferon-Driven Resistance Mechanisms to Immune Checkpoint Blockade Combination Therapy

Sonia Harnois, Bristol-Myers Squibb, Canada
Short Talk: Relatlimab, An Anti-LAG-3, in Combination with Nivolumab in Melanoma Patients Who Progressed on Anti-PD-1/PD-L1

Karin Knudson, NCI, National Institutes of Health, USA
Short Talk: An IL-15 Superagonist ALT803in Combination with an Anti-PD-L1

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Square Dorchester/Parc Mont Royal
19:30—22:00
Poster Session 1

Square Dorchester/Parc Mont Royal

SUNDAY, MARCH 25

07:30—08:30
Breakfast

Square Dorchester/Parc Mont Royal
08:30—11:30
Combining Immunotherapy with Tyrosine Kinase and Other Signaling Pathway Inhibitors
Meeting has ended...abstracts no longer viewable online.

Place du Canada
* Bahija Jallal, MedImmune, Inc., USA

Lisa M. Coussens, Oregon Health & Science University, USA
Dynamic Interactions between Myeloid and Lymphoid Cells Regulate Response to Therapy in Solid Tumors

Judith A. Varner, University of California, San Diego, USA
Targeting Tissue-Resident Macrophages and Their Progenitors to Suppress Cancer Progression

Coffee Break

Chris H. Boshoff, Pfizer Inc., USA
Combining Immune Checkpoint Inhibitors with Targeted Therapies

Jane L. Grogan, Genentech, Inc., USA
Epigenetic Regulation of Tumor-Associated Myeloid Cell Activity by CBP/EP300 Bromodomain

Sabrin Mishel, University of Toronto, Canada
Short Talk: Proximal Signaling through the Innate Immune Inhibitory Receptor Signal Regulatory Protein alpha (SIRPα) in Primary Macrophages

11:30—17:00
On Own for Lunch

11:30—13:00
Poster Setup

Square Dorchester/Parc Mont Royal
13:00—22:00
Poster Viewing

Square Dorchester/Parc Mont Royal
16:30—17:00
Coffee Available

Square Dorchester/Parc Mont Royal
17:00—19:00
Sequencing vs. Combinations: Insights from Biomarker and Preclinical Studies
Meeting has ended...abstracts no longer viewable online.

Place du Canada
* Lisa M. Coussens, Oregon Health & Science University, USA

Sergio A. Quezada, University College London, UK
Using Preclinical Models and Clinical Samples to Inform Mechanisms and Rational Combinations

Jo A. Van Ginderachter, VIB-Vrije Universiteit Brussel, Belgium
Tumor-Associated Dendritic Cell Sub-Populations in Cancer Immunity

Bernard A. Fox, Earle A Chiles Research Institute, USA
Sequencing Checkpoint Therapies

Ralf Huss, Definiens AG, Germany
Short Talk: Multiplex Immuno-Oncology Panel for Standardized Cancer Profiling of the Immune Status Based on the Spatial and Functional Characterization in the Tumor Microenvironment

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Square Dorchester/Parc Mont Royal
19:30—22:00
Poster Session 2

Square Dorchester/Parc Mont Royal

MONDAY, MARCH 26

07:30—08:30
Breakfast

Square Dorchester/Parc Mont Royal
08:30—11:30
Immunotherapy Combinations: Preventing and Managing Resistance to Checkpoint Inhibition and T Cell Exhaustion
Meeting has ended...abstracts no longer viewable online.

Place du Canada
* Sergio A. Quezada, University College London, UK

Peter S. Hammerman, Novartis Institutes for BioMedical Research, USA
Adaptive Resistance to Immune Checkpoint Blockade

Andrea Schietinger, Memorial Sloan Kettering Cancer Center, USA
Molecular and Epigenetic Programs Defining Tumor-Specific T Cell Dysfunction

Coffee Break

Gregory Lawrence Beatty, University of Pennsylvania, USA
Strategies for Incorporating CD40 Agonists in Cancer Therapy

Yong-Jun Liu, Sanofi, USA
Next Generation of Immunotherapy: Targeting Anti-PD1 Resistance

Ramsay Khadeir, Barts Cancer Institute, UK
Short Talk: Pegylated Arginine Deiminase and PD-1/PD-L1 Blockade in the Treatment of ASS1-Deficient Cancers

11:30—17:00
On Own for Lunch

11:30—13:00
Poster Setup

Square Dorchester/Parc Mont Royal
13:00—22:00
Poster Viewing

Square Dorchester/Parc Mont Royal
16:30—17:00
Coffee Available

Square Dorchester/Parc Mont Royal
17:00—19:00
Overcoming T Cell Exclusion and an Immune-Privileged Microenvironment with Combination Approaches
Meeting has ended...abstracts no longer viewable online.

Place du Canada
* Lieping Chen, Yale University, USA

Douglas T. Fearon, Cold Spring Harbor Laboratory, USA
CXCR4 Mediates Immune Privilege in T Cell-Excluded Tumors.

Daniela F. Quail, McGill University, Canada
Macrophage and T Cell Interactions in the Brain Tumor Microenvironment

Hiroyoshi Nishikawa, National Cancer Center Japan, Japan
Control of Tumor-Associated Regulatory T Cells for Effective Cancer Immunotherapy

Casey Ager, University of Texas MD Anderson Cancer Center, USA
Short Talk: Intratumoral Delivery of a Novel STING Agonist Synergizes with Checkpoint Blockade to Regress Multi-Focal Pancreatic Cancer

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Square Dorchester/Parc Mont Royal
19:30—22:00
Poster Session 3

Square Dorchester/Parc Mont Royal

TUESDAY, MARCH 27

07:30—08:30
Breakfast

Square Dorchester/Parc Mont Royal
08:30—11:30
Vaccines, Oncolytic Viruses and Cellular Therapies: Toward Combinations
Meeting has ended...abstracts no longer viewable online.

Place du Canada
* Mario Sznol, Yale School of Medicine, USA

Jeffrey Weber, New York University, USA
Clinical Efficacy and Biomarker Analyses in Patients Receiving Adjuvant Checkpoint Blockade for Resected High-Risk Stages III/IV Melanoma

Coffee Break

Olivera J. Finn, University of Pittsburgh School of Medicine, USA
Vaccines for Prevention of Non-Viral Cancers

Gerald P. Linette, University of Pennsylvania, USA
Melanoma Neoantigen Discovery and Clinical Validation

Annabelle J. Anandappa, Dana-Farber Cancer Institute, USA
Short Talk: Personal Neoantigen Vaccine for Glioblastoma Stimulates Neoepitope-Specific Intra-Tumoral T Cell Responses

11:30—17:00
On Own for Lunch

16:30—17:00
Coffee Available

Square Dorchester/Parc Mont Royal
17:00—18:45
CTLA-4: Novel Molecules and Approaches to Combinations
Meeting has ended...abstracts no longer viewable online.

Place du Canada
* Andrea Schietinger, Memorial Sloan Kettering Cancer Center, USA

Spencer C. Wei, University of Texas MD Anderson Cancer Center, USA
Cellular Mechanisms of Combination Checkpoint Blockade

Mario Sznol, Yale School of Medicine, USA
Lessons Learned from Anti-CTLA-4 and Anti-PD-1 Combination

Alan J. Korman, Bristol-Myers Squibb, USA
Next-Generation Anti-CTLA-4 Antibodies

18:45—19:00
Meeting Wrap-Up: Outcomes and Future Directions
Meeting has ended...abstracts no longer viewable online.

Place du Canada
* Chris H. Boshoff, Pfizer Inc., USA

* Lieping Chen, Yale University, USA

* Lisa M. Coussens, Oregon Health & Science University, USA

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Square Dorchester/Parc Mont Royal
20:00—23:00
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.

Square Dorchester/Parc Mont Royal

WEDNESDAY, MARCH 28

 
Departure


*Session Chair †Invited, not yet responded.



We gratefully acknowledge support for this conference from:


Directors' Fund


These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.



Keystone Symposia thanks our Sponsors for generously supporting this meeting:

BioLegend, Inc. Bristol-Myers Squibb Company
Cancer Research UK Cell Research
Genentech, Inc. Incyte Corporation
MedImmune Merck & Co., Inc.
OncoMed Pharmaceuticals, Inc. Pfizer Inc.
Regeneron Pharmaceuticals, Inc. Surface Oncology
Takeda Pharmaceutical Company Limited TESARO, Inc.
Thermo Fisher Scientific Inc.
 

We gratefully acknowledge additional support from these exhibitors at this conference:

Caprion Biosciences Inc. Immudex USA, LLC
Please stop by to meet these exhibitors during the conference.


We gratefully acknowledge the generous grant for this conference provided by:


National Institutes of Health

Grant No. 1 R13 CA224868-01

Funding for this conference was made possible (in part) by 1 R13 CA224868-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.


We gratefully acknowledge additional support for this conference from:

American Association for Cancer Research (AACR) American Society of Gene & Cell Therapy (ASGCT)
Avanti Polar Lipids, Inc. Bethyl Laboratories, Inc.
Charles River Eurofins Pharma Discovery Services
Infinity Pharmaceuticals, Inc.
 

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:



Celularity Inc.


Genentech, Inc.


Pfizer Inc.


We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676